Browsing: Weight Loss

John Goodmanis checking out a fresh new look after a major lifestyle transformation

Bank of America spends more than $250 million a year covering GLP-1 weight-loss medications for its employees, a benefit CEO Brian Moynihan says is paying off despite the drugs’ rapidly rising costs

Eli Lilly (NYSE: LLY) is already the leader in the weight-loss market thanks to Zepbound, the best-selling medication in this space. However, the drugmaker has been making headlines with its next-gen anti-obesity medicine, retatrutide. Eli Lilly recently announced that it will request approval from the U.S. Food and Drug Administration for retatrutide in the first…

The last time I spoke about Eli Lilly and Company (LLY), it was in a Seeking Alpha article entitled “Eli Lilly: ‘Strong Buy’ Raised Revenue Guidance By $2 Billion For 2026 And Label Expansions

Starbucks is pulling back coverage for weight-loss drugs, a reversal that comes as employers’ spending on popular GLP-1 medicines soars

If England’s obesity rates were still the same as 1993 there would be seven million fewer adults living with obesity

GLP-1 medications have become one of the most closely watched tools in metabolic health, and for good reason. These medications can help regulate appetite, improve blood sugar control, and drive levels of weight loss that were once difficult to achieve without surgery. But a new review of 19 clinical trials indicates that different GLP-1s can have…

CEO Brian Moynihan revealed Wednesday that Bank of America spends more than $250 million a year on GLP-1 weight loss drugs for its roughly 211,000 employees, calling the expenditure a sound investment in the people who work there

I didn’t start strength training because I wanted sculpted arms or visible abs, though I certainly wouldn’t complain about either. I started because I suddenly needed to be stronger

Arhood of Brooklyn, N.Y. on July 1, 2026. (Photo by Vincent Alban/For The Washington Post